A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Trial ID or NCT#
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors
- - Confirmed advanced solid malignancy - Life expectancy of at least 3 months - Age 18 years or older - Acceptable liver function - Acceptable renal function - Acceptable hematologic status
- - Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment. - Received non-investigational agent within 3 weeks before enrollment. - Progressive CNS involvement including the need of corticosteroids - Pregnant or breast-feeding women - Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1 - Known HIV infection
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office